Efficacy and safety of camrelizumab combined with FOLFOX as neoadjuvant therapy for patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy.

Yuzhou Zhao,Guangsen Han,Jing Zhuang,Zhimeng Li,Gangcheng Wang,Baodong Li,Jinbang Wang,Yanhui Gu,Pengfei Ma,Junli Zhang,Yanghui Cao,Chenyu Liu,Sen Li,Xijie Zhang

Efficacy and safety of camrelizumab combined with FOLFOX as neoadjuvant therapy for patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy.

2020

Yuzhou Zhao
Guangsen Han
Jing Zhuang
Zhimeng Li
Gangcheng Wang
Baodong Li
Jinbang Wang
Yanhui Gu
Pengfei Ma
Junli Zhang
Yanghui Cao
Chenyu Liu
Sen Li
Xijie Zhang

e16549Background: Neoadjuvant chemotherapy for patients with locally advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC) can improve the overall survival without increasing oper...

Keywords:

FOLFOX
Neoadjuvant therapy
Gastroenterology
Pathology
locally advanced
Radical gastrectomy
Internal medicine
Gastroesophageal Junction Adenocarcinoma
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations